Since Plk1 is required for tumor cell proliferation, the authors showed that rigosertib induced apoptotic activity against 94 tumor cell lines with a GI50 between 50–200 nM, resulting in tumor cell death by mitotic arrest, demonstrating its potential efficacy. This evidence concerns the gene PLK1 and neoplasm.